9 March 2016 – patent grant
The company has been granted a European patent for its Parsortix liquid biopsy system which harvests cancer cells from blood for medical analysis. This covers a range of uses and extends the duration of patent coverage to 2034. Recently the liquid biopsy market has been identified by several major US investment banks as an emerging multi- billion market and ANGLE’s Parsortix technology is one of a limited number of patent protected solutions. This patent extends the group’s intellectual property position and maintains the momentum of expanding patent coverage. We continue to rate the shares a LONG TERM BUY.